Author
Bin Wang: Conceived and designed the experiments; Performed the experiments; Wrote the paper.
Zhiling Li: Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data.
Funding
This work was supported by 10.13039/501100007162 Guangdong Science and Technology Department (No. 2016A020218015).
Results
Univariate analysis was first used to screen clinical factors associated with pregnancy in PCOS women. As shown in Table 1 , antral follicle count, basal LH, basal FSH, basal LH/FSH ratio, and the number of mature follicles on the trigger day were all factors contributing to pregnancy in women with PCOS, with basal LH being the most significant one (P < 0.001). Accordingly, in our further analyses, we mainly focused on the relation of basal LH with the reproductive outcomes in PCOS women. Table 1 Baseline characteristics and reproductive outcomes of pregnant and nonpregnant patients. Table 1 Characteristics Clinical pregnancy (n = 135) a Nonpregnancy (n = 398) a P value Age (years) 28 (20–38) 29 (21–40) 0.194 Duration of infertility (years) 3 (1.0–10) 3 (0.4–9) 0.162 Etiology of infertility Primary 99 (73.33%) 296 (74.37%) 0.812 Secondary 36 (26.67%) 102 (25.63%) Body mass index (kg/m 2 ) 21.8 (17.0–28.1) 22.0 (16.9–30.7) 0.216 Antral follicle count 26 (5–55) 24 (5–55) 0.047 Basal LH (mIU/ml) 9.13 (1.39–30.80) 6.98 (0.42–29.60) 0.000 Basal FSH (mIU/ml) 6.39 (2.9–50.8) 5.91 (0.9–11.8) 0.001 Basal LH/FSH ratio 1.604 (0.22–5.21) 1.393 (0.0–5.21) 0.026 Basal estradiol (pg/ml) 45 (6–119) 44 (6–405) 0.889 Basal progesterone (ng/ml) 0.355 (0.01–33.00) 0.345 (0.01–2.22) 0.800 Total dosage of gonadotrophin used (IU) 425 (75–2275) 450 (50–3575) 0.755 Endometrium thickness on the trigger day (mm) 10 (4.8–6.0) 10 (5.0–16.5) 0.769 Number of mature follicles on the trigger day 1.467 ± 0.747 1.328 ± 0.636 0.005 Abbreviation: LH, luteinizing hormone; FSH, follicle-stimulating hormone. Continuous data are presented as mean ± standard deviation or median (minimum-maximum) depending on distribution. Categorical data are expressed as number (percentage). a: missing data were addressed using the listwise deletion method.
Baseline characteristics and reproductive outcomes of pregnant and nonpregnant patients.
Abbreviation: LH, luteinizing hormone; FSH, follicle-stimulating hormone. Continuous data are presented as mean ± standard deviation or median (minimum-maximum) depending on distribution. Categorical data are expressed as number (percentage). a: missing data were addressed using the listwise deletion method.
ROC curve was employed to elucidate the predictive value of basal LH, basal FSH, basal LH/FSH ratio, antral follicle count and the number of mature follicles on the trigger day on achievement of clinical pregnancy in PCOS women. As illustrated in Fig. 2 A, the predictive power of basal LH was stronger when compared to other factors (areas under the ROC curve [AUC] 0.614, 95% confidence interval 0.558–0.670, for basal LH, P = 0.000). Further analysis revealed that the cut-off value of basal LH was 7.57 mIU/ml. Fig. 2 Receiver operating characteristic curve of antral follicle count, basal luteinizing hormone, basal follicle-stimulating hormone, bLH/FSH ratio, and the number of mature follicles of the trigger day in relation to the achievement of clinical pregnancy. AFC, antral follicle count; bLH, basal luteinizing hormone; bFSH, basal follicle-stimulating hormone; AUC, Areas under the receiver operating characteristic curve. Fig. 2
Receiver operating characteristic curve of antral follicle count, basal luteinizing hormone, basal follicle-stimulating hormone, bLH/FSH ratio, and the number of mature follicles of the trigger day in relation to the achievement of clinical pregnancy. AFC, antral follicle count; bLH, basal luteinizing hormone; bFSH, basal follicle-stimulating hormone; AUC, Areas under the receiver operating characteristic curve.
Next, we combined all the significant markers to produce a new ROC curve. Data from statistical analysis showed that AUC for the new curve was slightly improved when compared to any of the five individual markers abovementioned (0.650 vs. 0.556, 0.614, 0.590, 0.569, and 0.568, Fig. 2 B).
Based on quartile division, we subsequently analyzed the relation of basal LH level with major indicators of reproductive outcomes in PCOS women. As indicated in Table 2 and Fig. 3 A, as basal LH level increased (from <4.54 mIU/ml in the first quartile to 4.54–7.51 mIU/ml in the second quartile and 7.51–11.69 mIU/ml in the third quartile), clinical pregnancy rates steadily increased as well (from 12.78% of the first quartile to 23.52% of the second quartile and 31.81% of the third quartile, P 11.69 mIU/ml, the 75th percentile of basal LH concentration (33.33% of the fourth quartile vs. 31.81% of the third quartile). Accordingly, the relation between basal LH and pregnancy in women with PCOS resembled a stair-shaped curve. A similar stair-shaped relation was also found between basal LH and live birth rate (7.51%, 15.44%, 21.21%, and 21.96% for the first, the second, the third and the fourth quartile, respectively, P < 0.000, Table 2 and Fig. 3 C). In addition, early miscarriage rates gradually increased as basal LH level rose (3.0%, 3.67%, 4.54%, and 8.33% for the first, the second, the third, and the fourth quartile, respectively, P = 0.044, Table 2 and Fig. 3 B). Furthermore, the third and the fourth quartiles, with relatively higher basal LHs were associated with elevated multiple pregnancy rates (3.0% of both the third and fourth quartiles vs. 0.75% of the first quartile and 0% of the second quartile, Table 2 and Fig. 3 D). Table 2 Analysis of reproductive outcomes, antral follicle count and number of mature follicles on the trigger day based on quartile division of basal luteinizing hormone concentration. Table 2 Factors investigated Concentration of basal luteinizing hormone (n = 533) a P value P trend The first quartile The second quartile The third quartile The fourth quartile 11.69 mIU/ml (n = 132) Clinical pregnancy rate 17/133 (12.78%) 32/136 (23.52%) 42/132 (31.81%) 44/132 (33.33%) 0.000 0.000 Early miscarriage rate 4/133 (3.0%) 5/136 (3.67%) 6/132 (4.54%) 11/132 (8.33%) 0.183 0.044 Multiple pregnancy rate 1/133 (0.75%) 0/136 (0%) 4/132 (3.03%) 4/132 (3.03%) 0.116 0.048 Live birth rate 10/133 (7.51%) 21/136 (15.44%) 28/132 (21.21%) 29/132 (21.96%) 0.005 0.001 Antral follicle count 23.99 ± 5.52 25.13 ± 6.22 27.30 ± 8.53 28.28 ± 8.48 0.000 b NA Number of mature follicles on the trigger day 1.270 ± 0.524 1.308 ± 0.683 1.378 ± 0.693 1.462 ± 0.681 0.046 b NA Values are presented as number (percentage) or mean ± standard deviation. Data were first arranged in ascending order by basal luteinizing hormone concentration, and then divided into four quartiles with the 25th (4.54), the 50th (7.51) and the 75th (11.69) percentile of basal luteinizing hormone concentration as the three dividing points. Analysis was then carried out on this basis. a missing data were addressed using the listwise deletion method. b multiple comparisons were performed with the Kruskal-Wallis test due to abnormal distribution of the data analyzed. NA: not applicable. Fig. 3 Change of clinical pregnancy rate, early miscarriage rate, live birth rate, multiple pregnancy rate, antral follicle count (AFC), and number of mature follicles on the trigger day based on quartile division of basal luteinizing hormone concentration. Data were first arranged in ascending order by basal luteinizing hormone concentration and then divided into four quartiles with the 25th (4.54), the 50th (7.51), and the 75th (11.69) percentile of basal luteinizing hormone concentration as the three dividing points. Analysis and drawing were then carried out on this basis. Fig. 3
Analysis of reproductive outcomes, antral follicle count and number of mature follicles on the trigger day based on quartile division of basal luteinizing hormone concentration.
Values are presented as number (percentage) or mean ± standard deviation. Data were first arranged in ascending order by basal luteinizing hormone concentration, and then divided into four quartiles with the 25th (4.54), the 50th (7.51) and the 75th (11.69) percentile of basal luteinizing hormone concentration as the three dividing points. Analysis was then carried out on this basis.
missing data were addressed using the listwise deletion method.
multiple comparisons were performed with the Kruskal-Wallis test due to abnormal distribution of the data analyzed. NA: not applicable.
Change of clinical pregnancy rate, early miscarriage rate, live birth rate, multiple pregnancy rate, antral follicle count (AFC), and number of mature follicles on the trigger day based on quartile division of basal luteinizing hormone concentration. Data were first arranged in ascending order by basal luteinizing hormone concentration and then divided into four quartiles with the 25th (4.54), the 50th (7.51), and the 75th (11.69) percentile of basal luteinizing hormone concentration as the three dividing points. Analysis and drawing were then carried out on this basis.
Moreover, we also explored the relation between basal LH level and the number of mature follicles on the trigger day. Starting from the first to the fourth quartile, the number of mature follicles on the trigger day gradually rose as the basal LH level increased (P < 0.05, Fig. 3 E). Likewise, a similar relation between basal LH and antral follicle count was also noted (see Fig. 3 F).
Spearman rank correlation analysis was performed to investigate the relationship of basal LH with antral follicle count, number of mature follicles on the trigger day, clinical pregnancy, early miscarriage, and multiple pregnancies. As shown in Table 3 , basal LH was positively correlated with antral follicle count, number of mature follicles on the trigger day, clinical pregnancy, live birth, and multiple pregnancies (the correlation coefficients were 0.209, 0.119, 0.165, 0.118, and 0.094 respectively, all P < 0.05). Besides, the number of mature follicles on the trigger day was also positively correlated with clinical pregnancy, early miscarriage, and multiple pregnancies (all P < 0.05, see Table 3 ). Furthermore, besides the positive correlation between basal LH and antral follicle count, there was a positive correlation between antral follicle count and clinical pregnancy (all P < 0.05, see Table 3 ). Table 3 Correlation analysis among basal LH, clinical pregnancy, early miscarriage, live birth, multiple pregnancy, antral follicle count and number of mature follicles of the trigger day (n = 533). Table 3 Investigated characteristics a Clinical pregnancy Early miscarriage Live birth Multiple pregnancy AFC bLH Number of mature follicles on the trigger day Clinical pregnancy Correlation coefficient – 0.349** 0.866** 0.225** 0.088* 0.165** 0.121** P value – 0.000 0.000 0.000 0.047 0.000 0.005 Early miscarriage Correlation coefficient – – −0.118* 0.106* 0.054 0.071 0.090* P value – – 0.013 0.015 0.222 0.102 0.037 Live birth Correlation coefficient – – – 0.187** 0.025 0.118* 0.073 P value – – – 0.000 0.601 0.013 0.127 Multiple pregnancy Correlation coefficient – – – – 0.048 0.094* 0.087* P value – – – – 0.283 0.031 0.045 AFC Correlation coefficient – – – – – 0.209** 0.069 P value – – – – – 0.000 0.124 bLH Correlation coefficient – – – – – – 0.119** P value – – – – – – 0.006 Abbreviation: AFC, antral follicle count; bLH, basal luteinizing hormone. *, P < 0.05; **, P < 0.01. a: missing data were addressed using the listwise deletion method.
Correlation analysis among basal LH, clinical pregnancy, early miscarriage, live birth, multiple pregnancy, antral follicle count and number of mature follicles of the trigger day (n = 533).
Abbreviation: AFC, antral follicle count; bLH, basal luteinizing hormone. *, P < 0.05; **, P < 0.01. a: missing data were addressed using the listwise deletion method.
Material
Our study registered information from PCOS couples who received COS and IUI therapies at the Reproductive Center of The First Affiliated Hospital of Shantou University Medical College between January 1, 2016 and December 31, 2020. Demographic and clinical data were acquired through the electronic medical record. PCOS was diagnosed as per the Rotterdam Criteria [ 3 ]. The excluding criteria were the following: spousal sperm abnormality, women with body mass index (BMI) greater than 30 kg/m 2 , endometriosis, blockage of the oviduct and anomaly of uterus or pelvic cavity. As shown in Fig. 1 , 533 cycles of COS and IUI therapies were eventually included. Prior to initiation of COS and IUI, each couple received a routine infertility checkup in the Reproductive Center. For men, semen quality was assessed after 3–5 days of abstinence; for women, the basal hormone levels were tested on day 3–5 of the menstruation. Fig. 1 Flowchart illustrating subject selection. PCOS, polycystic ovary syndrome. Fig. 1
Flowchart illustrating subject selection. PCOS, polycystic ovary syndrome.
Our study was authorized by The Institutional Ethics Committee of our hospital (Authorization ID: 2015). All participants provided written informed consent. This study was conducted according to the principles of the Declaration of Helsinki.
The starting dose of ovarian stimulation was tailored by the fertility doctor after completely evaluating patients’ age, BMI, current ovarian reserve, and previous history of ovarian response. Ovarian stimulation was initiated 3–5 days after the menstrual cycle.
For ovarian stimulation utilizing human menopausal gonadotropin (HMG), stimulation was carried out as depicted in our previous study [ 21 ]. Similarly, for ovarian stimulation using clomiphene or letrozole, stimulation was performed as stated in our previous study [ 21 ].
Ovulation were induced either with 10,000 IU HCG (Livzon, China) or 0.25 mg rHCG (Merck Serono, Switzerland) or 0.1–0.2 mg GnRH-a (IPSEN PHARMA, France) plus 6000 IU HCG when at least one dominant follicle with a diameter of ≥18 mm had emerged. IUI was performed 24–36 h after the ovulation induction, with the help of a sterile catheter. Women were then advised to have bedrest for 30 min after the operation. Serum βeta-human chorionic gonadotropin (β-hCG) was measured 14 days after the IUI operation to ascertain the existence of pregnancy.
Beginning from the day after IUI, luteal support was given individually in the form of 10 mg Dydrogesterone (Abbott Laboratories, USA) 2 or 3 times each day for 15–16 days, with the supplement of 2000 IU hCG every three days when necessary. If a live intrauterine sac was confirmed, the luteal support was kept for 10-12 additional weeks.
Five or six weeks after the IUI operation, a transvaginal ultrasound scan was additionally conducted to detect clinical pregnancy; clinical pregnancy was documented if an intrauterine sac was present. Loss of a pregnancy during the first 12 weeks was considered as early miscarriage. Live birth was defined as the birth of a live born infant with a gestational age of > 28 weeks.
Concentration of hormone was determined using the method of chemiluminescence (Abbott Biologicals B·V., Weesp, Netherlands) with reference to producer's manual in the Department of Clinical Laboratory. Both inter-assay and intra-assay coefficients of variation were under 10% for all measurements.
Analysis of semen quality was performed in accordance to the World Health Organization Criteria in the Andrology Laboratory of our center. Two or 3 h before the prearranged time of insemination, semen samples were obtained by masturbation after 3–5 days of abstinence. Semen samples were then prepared using the density gradient centrifugation method as described in previous study [ 22 ].
Follow-up interviews started 2 weeks after the IUI operation and every other month after that. Senior nurses collected information concerning health condition and pregnancy via telephone calls. Follow-up interviews were cancelled if one of the below mentioned conditions happened: (1) no positivity of serum β-hCG 14 days after IUI; (2) early miscarriage; (3) birth of a viable infant. The follow-up rate of the current study was 100%.
Statistical analysis was conducted using the Statistic Package for Social Science 20.0 for Windows (SPSS 20.0, IBM, NY, USA). For continuous data, Kolmogorov-Smirnov normality test was first employed to ascertain the distribution. According to the type of distribution, continuous data were expressed as mean ± standard deviation or median (25th-75th percentiles). Normally distributed continuous data were analyzed with the T-test, and abnormally distributed continuous data were analyzed with the Mann-Whitney U test. For data with abnormal distribution, the Kruskal-Wallis H test was utilized to conduct multiple comparisons. Categorical data were shown as number or percentage. Categorical data were analyzed using Pearson's Chi-square or Fisher's exact tests. The receiver operating characteristic (ROC) curve was employed to elucidate the predictive value of specific factors on the achievement of clinical pregnancy. In ROC analysis, the occurrence of pregnancy (categorical variable, yes = 1, no = 0) was defined as the dependent variable, while bLH, bFSH, bLH/FSH ratio, AFC, and number of mature follicles of the trigger day were incorporated as the independent variables. Next, ROC analysis was conducted in the SPSS using the default settings. The value of AUC (area under the curve) reflects the predictive power of any specific factor on the occurrence of pregnancy. The AUC value was statistically significant only when the corresponding P value < 0.05. Quartile division was used to assist analysis of the relation between basal LH level and major indicators of reproductive outcomes. Data were first arranged in ascending order by basal LH concentration and then divided into 4 quartiles, with the 25th, the 50th, and the 75th percentile of basal LH concentration as the three dividing points. Additional analysis was then carried out on this basis. Spearman rank correlation analysis was conducted to investigate the correlation between two factors. Missing data were addressed using the listwise deletion method as suggested by SPSS. A two-tailed P value of 80%, as calculated by NCSS-PASS (NCSS Inc., USA, 2005 version).
Conclusion
Hypersecretion of basal LH was associated with an increased risk of pregnancy loss among PCOS women undergoing COS and IUI. Basal LH may have predictive value on pregnancy achievement in women with PCOS undergoing COS and IUI.
Discussion
LH is of essential importance in folliculogenesis and ovulation [ 10 ]. In addition, hypersecretion of basal serum LH is an essential hallmark of polycystic ovary syndrome (PCOS) [ 13 ]. Nevertheless, the prevalence of elevated basal LH or basal LH/FSH ratio can fluctuate between 35% and 77% among PCOS women [ 12 ]. As a result, the diagnostic value of basal LH or basal LH/FSH ratio on PCOS remains unclear and debatable [ 13 ].
Previous studies have explored the relationship of basal serum LH with the reproductive outcomes in PCOS patients; however, reported findings seem contradictory [ [14] , [15] , [16] , [17] , [18] , [19] ]. Moreover, as these previous studies were mainly performed in the context of IVF [ [14] , [15] , [16] , [17] , [18] , [19] ], the relationship between basal LH and reproductive outcomes in women with PCOS undergoing controlled ovarian stimulation (COS) and intrauterine insemination (IUI) remains unclear. Compared to IVF, IUI is a simple, less invasive, and low-cost technique [ 8 ]. This study focused on the relationship between basal LH and the reproductive outcomes in PCOS women who underwent COS and IUI. To our knowledge, this is the first report of this kind.
First, univariate analysis was used to explore possible contributing factors to pregnancy among PCOS women, finding that basal LH, basal FSH, basal LH/FSH ratio, antral follicle count, and the number of mature follicles on the trigger day were all factors contributing to pregnancy in PCOS women. However, basal LH was the most significant among all the analyzed factors, highlighting the critical role of basal LH in the pregnancy of PCOS women. These findings are consistent with previous studies from IVF settings [ 11 , 23 ].
In addition to basal LH, basal FSH could have clinical significance and is worthy of further study. It has been shown that basal luteinizing hormone concentration is elevated in PCOS while basal FSH remains unchanged or slightly suppressed [ 24 , 25 ]. In the present study, we found that the basal FSH levels in non-pregnant PCOS women were significantly lower compared to pregnant PCOS women. Blank et al. argued that insufficient FSH level contributes to impaired follicular development [ 26 ], which may partly explain the findings of the present study. In our future study, we will analyze the effect of basal FSH on reproductive outcomes in PCOS women undergoing COS and IUI.
ROC curve was used to examine the predictive value of the factors above on pregnancy in PCOS women. According to the findings from univariate analysis, the predictive value of basal LH was higher than other factors (AUC of 0.614 for basal LH). However, even though an AUC of 0.614 indicated a relatively low accuracy, it can still be interpreted as reasonable, considering that pregnancy in PCOS women is co-determined by multiple factors, with basal LH just being one of them [ 5 ]. Moreover, the cut-off value of basal LH was 7.57 mIU/ml in this study, suggesting that, under the IUI setting, PCOS women with basal LH of 7.57 mIU/ml were most likely to achieve pregnancy. We also combined all the significant markers to produce a new ROC curve. Data from statistical analysis showed that AUC for the new curve was slightly improved when compared to any of the five individual markers (0.650 vs. 0.556, 0.614, 0.590, 0.569, and 0.568, Panel B of Fig. 2 ), thus suggesting that pregnancy in women with PCOS may also be influenced by other important factors that were not included or analyzed in the current study.
With quartile division, we explored the relation of basal LH with major indicators of reproductive outcomes in women with PCOS, finding a stair-shaped relation between basal LH and pregnancy and a positive linear relation between basal LH and early miscarriage. The stair-shaped relation between basal LH and pregnancy implies that as basal LH level exceeds the third cutting point (11.69 mIU/ml, the 75th percentile of basal LH level), the difficulty in achieving pregnancy considerably increases for PCOS women. Similarly, the positive linear relation between basal LH and early miscarriage revealed that, as basal LH level increases, the possibility of pregnancy loss increases accordingly. Furthermore, as complementary evidence to the previous finding, a stair-shaped relation was also observed between basal LH and live birth, which is a more reliable endpoint for the reproductive outcome. The stair-shaped relation between basal LH and live birth suggested that, as basal LH rises, the difficulty of sustaining the fetus increases, especially when basal LH exceeds the third cutting point (11.69 mIU/ml). Considering the previous findings, we believe that hypersecretion of basal LH may be associated with pregnancy loss.
Moreover, 11.69 mIU/ml, the 75th percentile of basal LH concentration, above which early miscarriage grew significantly while pregnancy and live birth ceased to increase, was close to 10 mIU/ml, a threshold value taken by Regan et al. to define high or low LH group [ 27 ]. Regan and colleagues found that serum LH concentration >10 mIU/ml on day 8 of the menstrual cycle was significantly associated with fertility impairment and increased miscarriage among women with regular menstrual cycles [ 27 ]. A similar phenomenon was also observed among PCOS women in the present study. Regan et al. even suggested that basal LH might be a powerful predictor of miscarriage, irrespective of obstetric history [ 27 ]. A previous study has proposed that high follicular-phase LH levels, rather than the presence of polycystic ovaries, predicted the poor prognosis of fertility among PCOS women [ 28 ]. Our results showed that basal serum LH of 11.69 mIU/ml may be used as a reference value by fertility doctors treating PCOS patients who intend to undergo COS and IUI treatments.
Besides, we discovered that the number of mature follicles on the trigger day was positively correlated with clinical pregnancy, early miscarriage, and multiple pregnancies. In addition to the positive correlation of basal LH with antral follicle count (a faithful indicator for ovarian reserve and ovarian responsiveness to drug stimulation [ 29 , 30 ]), there was also a positive correlation between antral follicle count and clinical pregnancy in our study. Accordingly, we believe that PCOS women with a high level of basal LH may have a high ovarian reserve and a high responsiveness to the drug of ovarian stimulation. Hence, it is rational to conclude that PCOS women with high levels of basal LH may yield more mature follicles after undergoing ovarian stimulation compared to those with low levels of basal LH. In turn, more mature follicles may enhance the chance of pregnancy. However, we did not observe an uninhibited pregnancy rise (or live birth) as basal LH increased. Instead, the relation of these two indicators resembled a stair-shaped curve. This seemingly paradoxical discovery implies that more mature follicles associated with high basal LH and high ovarian responsiveness may impair fertilization competence, or the ensuing embryo may have poor survival and be easily aborted.
The mechanism underlying the association between hypersecretion of basal LH and miscarriage remains to be elucidated. Usually, the preovulatory follicle arrests at the diplotene stage of the first meiotic division and remains dormant, waiting for further stimulus [ 27 ]. When LH enters the preovulatory follicle at the midcycle of menstruation, the meiotic division resumes and produces a mature oocyte about 36 h later [ 27 ]. It is believed that there is a species-specific time window between the completion of the first meiotic division of the oocyte and its fertilization, during which conditions for fertilization and embryonic development are optimal [ 31 , 32 ]. If the time window is extended by premature exposure to an ovulatory stimulus (LH, for instance), fertilization is impaired and the ensuing embryo has poor survival and is more likely to be aborted [ 31 , 32 ].
We support the hypothesis proposed by Baker et al. [ 32 ], suggesting that LH is persistently high throughout the follicular phase in most PCOS women. This hormone may penetrate the follicle and cause the oocyte to mature prematurely, eventually resulting in a physiologically “aged” oocyte. Such oocytes may have impaired fertilization capacity or produce an embryo that implants poorly and is easily aborted [ 33 ]. Regardless of the potential mechanism, an elevated level of basal serum LH during the follicular phase leads to an increased risk of pregnancy loss among PCOS women undergoing COS and IUI. Our results suggest that basal serum LH may have predictive value for the achievement of pregnancy among PCOS women undergoing COS and IUI.
There are some shortcomings to our study. Firstly, this was a retrospective study, which should be considered when interpreting our results. Future prospective randomized studies are needed to further verify our results. Secondly, our study was conducted in a single center and had a relatively small sample size. Therefore, reported findings should be further validated by a multi-center clinical trial with sufficient samples in the future.
Introduction
Polycystic ovary syndrome (PCOS) is currently the most common endocrine disease among women of reproductive age, affecting 20% of infertile women [ 1 , 2 ]. On ultrasound examination, PCOS is clinically characterized by oligo-anovulation, hyperandrogenism, and polycystic ovaries [ 3 ]. However, there is still no effective therapy for PCOS, and currently used strategies mainly focus on relieving symptoms and adopting a healthy lifestyle to minimize the possibility of complications [ 4 ]. Women with PCOS encounter difficulties in conceiving offspring due to oligo-anovulation [ 5 ]. Fortunately, controlled ovarian stimulation (COS) may help women with PCOS to get over this barrier and restore ovulation [ 6 , 7 ].
Intrauterine insemination (IUI) is a widely-used technique in assisted reproduction. This approach is commonly adopted before proceeding to complicated method of in vitro fertilization (IVF) and embryo transfer, as it can improve the chance of pregnancy whilst being easy and simple to perform, less invasive and relatively low-cost [ 8 ]. COS and IUI are now considered the first-line treatment for infertile couples with PCOS [ 9 ].
Luteinizing hormone (LH), a glycoprotein secreted by the pituitary gland, is thought to have a critical role in the follicle's steroidogenesis, growth, and final maturation [ 10 ]. However, the optimal level of LH during ovarian stimulation remains unclear [ 11 ]. Furthermore, although most PCOS women are featured by hypersecretion of basal LH, basal LH within the normal range may also be found in a small proportion of PCOS women due to disease heterogeneity [ 12 ]. Hence, the diagnostic value of basal LH on PCOS remains controversial [ 13 ].
Previous studies have shown that basal LH is associated with reproductive outcomes in PCOS women; however, reported findings are somewhat inconsistent [ [14] , [15] , [16] , [17] , [18] , [19] ]. Moreover, all previous studies were conducted in the context of IVF [ [14] , [15] , [16] , [17] , [18] , [19] ], leaving the association between basal LH and reproductive outcomes in women with PCOS undergoing IUI largely unknown and warranting further investigations. Consensus in reproductive medicine recommends at least three cycles of IUI for infertile PCOS women before switching to IVF [ 20 ]. A previous retrospective study also showed that the cumulative clinical pregnancy rate per patient might reach 38.59% after 3 cycles of IUI [ 20 ]. Therefore, studying influencing factors on reproductive outcomes in women with PCOS undergoing IUI is necessary.
In the present study, we retrospectively investigated the possible association of basal LH with reproductive outcomes in PCOS women who underwent COS and IUI in the present center. To our knowledge, this is the first report of this kind, and it will hopefully provide more information to better understand the association of basal LH with reproductive outcomes of PCOS women undergoing IUI.
Coi Statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Data Availability
Data will be made available on request.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.